1. Downsizing of locally advanced stage III (bulky) BRAF V600E/K melanoma with combination targeted therapy to achieve R0 resection. (February 2017) Authors: Haanen, J.; Blank, C.; Van Thienen, H.; Mallo, H.; Adriaansz, S.; Ter Meulen, S.; Madu, M.; Pronk, L.; Van der Hiel, B.; Van de Wiel, B.; Peeper, D.; Van Akkooi, A. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. High response rates after neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma, REDUCTOR trial. Issue 2 (February 2019) Authors: Blankenstein, S.; Rohaan, M.; Klop, M.; Van der Hiel, B.; Van de Wiel, B.; Peeper, D.; Haanen, J.; van Akkooi, A. Journal: European journal of surgical oncology Issue: Volume 45:Issue 2(2019) Page Start: e6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗